Massive 10-year study tracks real-world impact of lung-scarring drug
NCT ID NCT07080125
Summary
This study is following 2000 patients for up to 10 years to see how well the approved drug nintedanib works long-term for people with lung scarring caused by scleroderma. Researchers will track how the disease progresses, measure survival rates, and check if the drug improves patients' quality of life. The goal is to better understand the real-world benefits and risks of this treatment over many years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EUSTAR Registry
Basel, 4051, Switzerland
Conditions
Explore the condition pages connected to this study.